Research Center for Toxicology and Hygienic Regulation of Biological Products — Branch of the National Research Center — Institute of Immunology Federal Medico-Biological Agency
Auto-generated profile, based on publicly available information
Nikolay M. Onatsky
Research Center for Toxicology and Hygienic Regulation of Biological Products — Branch of the National Research Center — Institute of Immunology Federal Medico-Biological Agency
BACKGROUND: The incidence of food allergy in adults and children is very high. The key approach in the therapy of food allergy can be quality drug selection. New synthetic derivatives of fullerene, a high-tech hydrocarbon, can become such drugs. A unique biocompatible method for obtaining a stable aqueous dispersion of fullerene C60 (ADF-C60) as the main component for drugs for the treatment of allergic diseases has been developed. In this article, reproductive toxicity of the drug ADF-C60, currently in preclinical safety studies, was studied in female white outbred rats. Due to its properties, the ADF-C60 is promising for treatment of food allergy and can presumably be used during pregnancy. AIM: Preclinical study of reproductive toxicity of an ADF-C60 in the antenatal and postnatal periods of rat offspring development with oral administration to the mother generation during pregnancy. MATERIALS AND METHODS: Female rats were orally administered the ADF-C60 in 1-, 5-, and 50-fold therapeutic doses recommended for humans during the whole pregnancy. The general parameters of embryotoxic and teratogenic effects of the ADF-C60 before and after birth were studied. RESULTS: No evidence of embryotoxic and teratogenic effects of the ADF-C60 was found during the study of gestational parameters and general fetuses development. No adverse effects of the ADF-C60 were revealed during observation of postnatal development of offspring. CONCLUSION: ADF-C60 for the treatment of food allergy has no reproductive toxicity at doses up to 50 times higher than the therapeutic dose. After the conducted experiments it is possible to assume a significant probability of using the ADF-C60 during pregnancy, but additional preclinical and clinical studies are required to substantiate the obtained conclusion.
AIMS: To evaluate the antiallergic activity of an aqueous dispersion of fullerene C60 (ADF) and its safety in preclinical studies. MATERIALS AND METHODS: Food allergy was induced in BALB/c mice by ovalbumin. ADF was administered intragastrically in different regimens. Specific IgE, Th2 cytokines, body weight, diarrhea, and jejunal histology were assessed. Allergenicity was tested in mice and guinea pigs using standard hypersensitivity assays, and immunotoxicity was evaluated in humoral, cellular, and phagocytic immunity models. RESULTS: ADF reduced OVA-specific IgE, IL-4 and IL-5, alleviated diarrhea, and supported weight gain. Histology showed decreased eosinophilia in the jejunum. No allergenic or immunotoxic effects were detected in preclinical tests.